measurement of individual lesions and, therefore, a specific mark for a specific patient might not represent the true state of affairs; but in randomly selected groups these inaccuracies will mutually compensate and not bias the result. The method has the great advantage that when the MCV at three months of two groups of patients is compared, one is in fact comparing the total response to treatment of all manifestations of the cancer in these groups. The response of every individual lesion in every patient has had its effect on the resulting figure and this should provide far greater accuracy than the use of success rates.
There is one final factor which is seldom considered, but of great importance in assessing any treatment in a clinical trial. This is the ability of the patient to cope both physically and mentally with the condition of life that this treatment has given her. This is not easy to measure and certainly presents formidable difficulties in statistical comparison but it can be done and is an essential part of any clinical trial. We set our patients a fairly extensive questionnaire which was originally designed for this purpose by Dr H Eisenberg of the Connecticut State Department of Health. This questionnaire thoroughly tests the patient's ability to cope with everyday life after treatment. It is used by a trained interviewer at three and fifteen months after treatment and, by suitable coding, the results can be subjected to statistical analysis. These results can play an essential part in any comparison.
Professor R McWhirter (Royal Infirmary, Edinburgh)
Clinical Trial Undertaken in Breast Cancer in South-East Scotland While first proposed in 1941, it was not until April 1964 that agreement was reached that a clinical trial should be undertaken so that the results from radical mastectomy alone might be compared with those from simple mastectomy combined with radiotherapy.
It was agreed that the investigation would be limited to women in the age group 35-69 years. Patients with bilateral breast cancer and patients with previous or concurrent malignant disease in any other site are not included.
It was further agreed that ovariectomy would be performed in all patients under 60 years of age. Previously ovariectomized patients and patients in whom the breast cancer is associated with pregnancy or lactation are excluded.
All patients must be seen by a surgeon and a radiotherapist before any form of treatment so as to ensure that every patient admitted to the trial will be equally suitable for either form of treatment. In particular it should be noted that patients with active pulmonary tuberculosis or severe peripheral vascular disease and patients with tumours situated in the axillary tail of the breast are unsuitable for treatment by simple mastectomy and radiotherapy.
According to the clinical findings, and following radiographic examination of the chest and pelvis, all patients referred for the breast trial are staged according to the International Classification introduced in 1960. Acceptance is limited to patients in Stages I and II and some of the less advanced cases in Stage III.
To avoid conscious selection of the method of treatment the following system of random allocation has been adopted. An equal number of cards bearing the words 'radical mastectomy' and 'simple mastectomy and radiotherapy' are put in sealed envelopes. On receipt of the appropriate information a member of the office staff withdraws an envelope and the patient is then treated according to the information on the enclosed card. If at the time of treatment the surgeon finds on frozen section that the tumour is not malignant, the patient is of course excluded from the trial and the card bearing the treatment intended is returned to the box.
The first important requirement in any clinical trial is that it will be conducted on an ethical basis. That is to say those engaged in the trial must feel satisfied that they do not know beforehand whether one method of treatment is better than the other. For this very reason any difference in the results is likely to be small.
Small differences are difficult to detect and it is important to ensure that any difference which may be obtained will be due to a difference in the value of the two methods of treatment and not to other factors. Some factors, for example the clinical extent of the disease, can exert a marked influence and indeed this influence may be greater than that exerted by any difference in the value of the two methods of treatment. The second important requirement in a trial must therefore be to ensure that the two groups of patients will be as comparable in all material aspects as possible.
If the number of patients entering the trial were infinitely large, random allocation would suffice to ensure that the two groups of patients were comparable. In most centres, however, the number of patients available for the trial is such that the usually adopted system of random allocation may not produce two groups of patients comparable in all respects. This point becomes of increasing importance when the trial is extended to include as many patients as possible.
The conclusions which may be drawn from a trial apply only to the category or categories of patients included in the trial. If only one welldefined category is used to test the value of the treatment methods, comparable groups ofpatients will be obtained without much difficulty but the trial will be of limited value. When several categories, differing say in respect of age and extent of disease, are included the value of the trial is greatly enhanced. With the number of patients usually available, more elderly patients or more patients with advanced disease may be included in one of the groups. Such a distribution could easily result in a wrong conclusion being reached. This difficulty can be overcome by adopting a more refined method of randomization.
When the trial was being designed in Edinburgh it was decided to take the age of the patient and the extent of the disease into account.
Three age groups were recognized: (1) Staging is a convenient method of grouping together patients with disease of comparable extent and all patients accepted for the trial have been subdivided as follows: (1) Stage I cases.
(2) Stage II cases. (3) The less advanced cases in Stage III.
This makes three subdivisions in respect of age and three in respect of the extent of disease, or nine categories in all. To ensure equal distribution of each of the nine categories in the two groups of patients treated, the sealed envelopes are distributed in nine boxes. In each box there are an equal number of cards inscribed with the two methods of treatment. The method of random allocation of treatment in any patient still remains quite simple. Given the age of the patient and the stage of the disease, a card is withdrawn from the appropriate box.
From the numbers so far referred it has been estimated that approximately 100 patients will be admitted to the trial each year. Bearing in mind the overriding condition that all patients must be equally suitable for either method of treatment, the investigation has been extended to cover as wide a range of patients as possible. At the same time it would appear that the method of randomization adopted will ensure that the two groups of patients will be as nearly comparable as it is possible to make them.
Dr D A G Galton (Chester Beatty Research Institute, London)
Clinical Trials in Progress: Leukemia and Multiple Myeloma The first therapeutic trials in leukemia were begun in September 1959 by a working party set up by the Medical Research Council under the Chairmanship of Professor L J Witts.1 There are 14 participating centres, some of which operate through several co-operating hospitals. Seven trials have been started; two have been completed, one was redesigned, and four are in progress.
Chronic Granulocytic Leukemia
The main trial, a comparison of busulphan and radiation in the treatment of chronic granulocytic leukvmia, is still in progress. Until February 1964 splenic irradiation was used for the 'radiotherapy' patients, but has since been replaced by radioactive phosphorus administered intravenously. This long-term trial has run very smoothly, and loss to follow up, through removal from the district, or death from unrelated causes, has been infrequent. But the disease is rare, and the rate of entry low. In the first five years only 117 cases were notified; 2 had to be rejected because of diagnostic error, and 2 because death occurred before treatment was started, within a preselected period of forty-eight hours of admission to the trial.
Only untreated patients are accepted, and some of these may have to be excluded for various reasons, usually non-medical. For example, the 50 % chance of allocation to a radiotherapy schedule has to be considered in the case of wageearning patients referred from a distance. The frequent attendances necessary for radiotherapy would involve unnecessary hardship, for these patients could be equally well treated locally by busulphan. On the other hand, many eligible patients for whom inclusion in the trial would involve no hardship are certainly being lost to the trial, and many who are referred are ineligible because they have already received chemotherapy. Acute Leuka?mia Separate trials have been designed for children (below 14 years of age) and adults (above age 14). The aim of the first trials in children and adults was to compare the effect of 6-mercaptopurine, administered at a standard daily dosage of 2-5 mg per kg of body weight in combination with prednisone at high (250 mg daily) and low (40 mg 
